Pub Date : 2024-10-18DOI: 10.1016/j.kint.2024.08.028
Hiba Hamdan , Baback Roshanravan
Persons with end-stage kidney disease treated with dialysis experience distressing reductions in quality of life and increased mortality. Few large, randomized trials in nephrology have reported on health-related quality of life. Rose et al. report beneficial effects of high-volume hemodiafiltration versus high-flux hemodialysis on secondary end points of health-related quality of life in the CONVINCE trial (Comparison of High Dose Hemodiafiltration with High Flux Hemodialysis Trial). These results raise questions regarding hemodiafiltration as a potential modality to preserve health-related quality of life in end-stage kidney disease.
{"title":"Dialysis modality and quality of life: more answers yet more questions","authors":"Hiba Hamdan , Baback Roshanravan","doi":"10.1016/j.kint.2024.08.028","DOIUrl":"10.1016/j.kint.2024.08.028","url":null,"abstract":"<div><div>Persons with end-stage kidney disease treated with dialysis experience distressing reductions in quality of life and increased mortality. Few large, randomized trials in nephrology have reported on health-related quality of life. Rose <em>et al.</em> report beneficial effects of high-volume hemodiafiltration versus high-flux hemodialysis on secondary end points of health-related quality of life in the CONVINCE trial (Comparison of High Dose Hemodiafiltration with High Flux Hemodialysis Trial). These results raise questions regarding hemodiafiltration as a potential modality to preserve health-related quality of life in end-stage kidney disease.</div></div>","PeriodicalId":17801,"journal":{"name":"Kidney international","volume":"106 5","pages":"Pages 792-794"},"PeriodicalIF":14.8,"publicationDate":"2024-10-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142468929","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-10-18DOI: 10.1016/j.kint.2024.07.017
Hailin Zhao , Xianghong Luo , Zhaowei Zhou , Juying Liu , Catherine Tralau-Stewart , Andrew J.T. George , Daqing Ma
{"title":"Corrigendum to “Early treatment with xenon protects against the cold ischemia associated with chronic allograft nephropathy in rats.” Kidney International 2013;85:112–123","authors":"Hailin Zhao , Xianghong Luo , Zhaowei Zhou , Juying Liu , Catherine Tralau-Stewart , Andrew J.T. George , Daqing Ma","doi":"10.1016/j.kint.2024.07.017","DOIUrl":"10.1016/j.kint.2024.07.017","url":null,"abstract":"","PeriodicalId":17801,"journal":{"name":"Kidney international","volume":"106 5","pages":"Page 1001"},"PeriodicalIF":14.8,"publicationDate":"2024-10-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142486336","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-10-18DOI: 10.1016/j.kint.2024.08.008
Savas Ozturk , Serhan Tuglular , Refik Olmaz , Ismail Kocyigit , Muge Uzerk Kibar , Kenan Turgutalp , Dilek Torun , Tuncay Sahutoglu , Ozlem Usalan , Ozkan Gungor , Ramazan Danis , Gursel Yildiz , Ali Gurel , Mehmet Horoz , Mehmet Kucuksu , Suleyman Karakose , Tolga Yildirim , Mehmet Riza Altiparmak , Mehmet Deniz Ayli , Murat Tugcu , Mehmet Sukru Sever
This study investigated in-hospital outcomes and related factors in patients diagnosed with postearthquake crush syndrome after the earthquakes in Kahramanmaraş, Türkiye. One thousand twenty-four adult patients diagnosed with crush syndrome were analyzed. Data on demographic characteristics, clinical presentation, laboratory values, treatments, and outcomes were collected. A total of 9.8% of patients died during their hospital stay. Nonsurvivors were generally older, more likely to have preexisting chronic kidney disease, and faced more severe injuries and complications, including hypotension-shock, arrhythmias, elevated markers of renal dysfunction, and higher rates of acute kidney injury (AKI) and compartment syndrome. In addition, intensive care unit needs were higher. Multivariate analysis confirmed that age, injury severity, shock, high potassium, uric acid, and lactate levels on admission, development of AKI, compartment syndrome, and intensive care unit admission were significant predictors of mortality. Better disaster preparedness and improved health care infrastructure could be potential explanations for improved in-hospital mortality in the current era, as compared to previous earthquakes.
{"title":"Patients with crush syndrome and kidney disease: lessons learned from the earthquake in Kahramanmaraş, Türkiye","authors":"Savas Ozturk , Serhan Tuglular , Refik Olmaz , Ismail Kocyigit , Muge Uzerk Kibar , Kenan Turgutalp , Dilek Torun , Tuncay Sahutoglu , Ozlem Usalan , Ozkan Gungor , Ramazan Danis , Gursel Yildiz , Ali Gurel , Mehmet Horoz , Mehmet Kucuksu , Suleyman Karakose , Tolga Yildirim , Mehmet Riza Altiparmak , Mehmet Deniz Ayli , Murat Tugcu , Mehmet Sukru Sever","doi":"10.1016/j.kint.2024.08.008","DOIUrl":"10.1016/j.kint.2024.08.008","url":null,"abstract":"<div><div>This study investigated in-hospital outcomes and related factors in patients diagnosed with postearthquake crush syndrome after the earthquakes in Kahramanmaraş, Türkiye. One thousand twenty-four adult patients diagnosed with crush syndrome were analyzed. Data on demographic characteristics, clinical presentation, laboratory values, treatments, and outcomes were collected. A total of 9.8% of patients died during their hospital stay. Nonsurvivors were generally older, more likely to have preexisting chronic kidney disease, and faced more severe injuries and complications, including hypotension-shock, arrhythmias, elevated markers of renal dysfunction, and higher rates of acute kidney injury (AKI) and compartment syndrome. In addition, intensive care unit needs were higher. Multivariate analysis confirmed that age, injury severity, shock, high potassium, uric acid, and lactate levels on admission, development of AKI, compartment syndrome, and intensive care unit admission were significant predictors of mortality. Better disaster preparedness and improved health care infrastructure could be potential explanations for improved in-hospital mortality in the current era, as compared to previous earthquakes.</div></div>","PeriodicalId":17801,"journal":{"name":"Kidney international","volume":"106 5","pages":"Pages 771-776"},"PeriodicalIF":14.8,"publicationDate":"2024-10-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142486277","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
The efficacy and safety of rituximab in childhood steroid-resistant nephrotic syndrome (SRNS) remains unclear. Therefore, we conducted a retrospective cohort study at 28 pediatric nephrology centers from 19 countries in Asia, Europe, North America and Oceania to evaluate this. Children with SRNS treated with rituximab were analyzed according to the duration of calcineurin inhibitors (CNIs) treatment before rituximab [6 months or more (CNI-resistant) and under 6 months]. Primary outcome was complete/partial remission (CR/PR) as defined by IPNA/KDIGO guidelines. Secondary outcomes included kidney failure and adverse events. Two-hundred-forty-six children (mean age, 6.9 years; 136 boys; 57% focal segmental glomerulosclerosis, FSGS) were followed a median of 32.4 months after rituximab. All patients were in non-remission before rituximab. (146 and 100 children received CNIs for 6 month or more or under 6 months before rituximab, respectively). In patients with CNI-resistant SRNS, the remission rates (CR/PR) at 3-, 6-, 12- and 24-months were 26% (95% confidence interval 19.3-34.1), 35.6% (28.0-44.0), 35.1% (27.2-43.8) and 39.1% (29.2-49.9), respectively. Twenty-five patients were in PR at 12-months, of which 22 had over 50% reduction in proteinuria from baseline. The remission rates among children treated with CNIs under 6 months before rituximab were 42% (32.3-52.3), 52% (41.8-62.0), 54% (44.3-64.5) and 60% (47.6-71.3) at 3-, 6-, 12-, and 24-months. Upon Kaplan-Meier analysis, non-remission and PR at 12-months after rituximab, compared to CR, were associated with significantly worse kidney survival Adverse events occurred in 30.5% and most were mild. Thus, rituximab enhances remission in a subset of children with SRNS, is generally safe and CR following rituximab is associated with favorable kidney outcome.
{"title":"An international, multi-center study evaluated rituximab therapy in childhood steroid-resistant nephrotic syndrome.","authors":"Eugene Yu-Hin Chan,Aditi Sinha,Ellen Lm Yu,Naureen Akhtar,Andrea Angeletti,Arvind Bagga,Sushmita Banerjee,Olivia Boyer,Chang-Yien Chan,Anna Francis,Gian Marco Ghiggeri,Riku Hamada,Pankaj Hari,Nakysa Hooman,Luke Sydney Hopf,Mohamad Ikram I,Iftikhar Ijaz,Dmytro D Ivanov,Suprita Kalra,Hee Gyung Kang,Laura Lucchetti,Francesca Lugani,Alison Lap-Tak Ma,William Morello,María Dolores Camargo Muñiz,Subal Kumar Pradhan,Larisa Prikhodina,Reem H Raafat,Rajiv Sinha,Sharon Teo,Kouki Tomari,Marina Vivarelli,Hazel Webb,Hui Kim Yap,Desmond Yat-Hin Yap,Kjell Tullus","doi":"10.1016/j.kint.2024.09.011","DOIUrl":"https://doi.org/10.1016/j.kint.2024.09.011","url":null,"abstract":"The efficacy and safety of rituximab in childhood steroid-resistant nephrotic syndrome (SRNS) remains unclear. Therefore, we conducted a retrospective cohort study at 28 pediatric nephrology centers from 19 countries in Asia, Europe, North America and Oceania to evaluate this. Children with SRNS treated with rituximab were analyzed according to the duration of calcineurin inhibitors (CNIs) treatment before rituximab [6 months or more (CNI-resistant) and under 6 months]. Primary outcome was complete/partial remission (CR/PR) as defined by IPNA/KDIGO guidelines. Secondary outcomes included kidney failure and adverse events. Two-hundred-forty-six children (mean age, 6.9 years; 136 boys; 57% focal segmental glomerulosclerosis, FSGS) were followed a median of 32.4 months after rituximab. All patients were in non-remission before rituximab. (146 and 100 children received CNIs for 6 month or more or under 6 months before rituximab, respectively). In patients with CNI-resistant SRNS, the remission rates (CR/PR) at 3-, 6-, 12- and 24-months were 26% (95% confidence interval 19.3-34.1), 35.6% (28.0-44.0), 35.1% (27.2-43.8) and 39.1% (29.2-49.9), respectively. Twenty-five patients were in PR at 12-months, of which 22 had over 50% reduction in proteinuria from baseline. The remission rates among children treated with CNIs under 6 months before rituximab were 42% (32.3-52.3), 52% (41.8-62.0), 54% (44.3-64.5) and 60% (47.6-71.3) at 3-, 6-, 12-, and 24-months. Upon Kaplan-Meier analysis, non-remission and PR at 12-months after rituximab, compared to CR, were associated with significantly worse kidney survival Adverse events occurred in 30.5% and most were mild. Thus, rituximab enhances remission in a subset of children with SRNS, is generally safe and CR following rituximab is associated with favorable kidney outcome.","PeriodicalId":17801,"journal":{"name":"Kidney international","volume":"82 1","pages":""},"PeriodicalIF":19.6,"publicationDate":"2024-10-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142431127","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
扫码关注我们
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号